Temozolomide and irinotecan combination chemotherapy in patients with a specific subgroup of colorectal cancer and with circulating tumor DNA positivity after standard post-operative treatment
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2540916
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To assess the activity in terms of seroreversion of temozolomide and irinotecan (TEMIRI) consolidation regimen administered to patients with high-risk stage II (pT4) or III microsatellite stable, MGMT silenced CRC and positive post-adjuvant ctDNA after standard oxaliplatin-based adjuvant chemotherapy.
Primary endpoints: The activity of TEMIRI will be measured as the rate of patients with post-treatment seroreversion and disease-free at 2 years.
创建时间：
2021-03-15
